Exide Tops ₹5,200 Crore in EV Battery Bet as Bengaluru Plant Goes Live

Exide Industries has now committed ₹5,202.23 crore to a single battery subsidiary, closed the latest ₹99.99 crore tranche of that commitment just yesterday, and switched on the plant it has been funding less than a week ago.

That is a landmark figure for the Indian energy storage sector, and the timing is what makes it worth reading closely.

Exide Energy Solutions Limited (EESL) has crossed a threshold. It is no longer a construction project on a balance sheet; it is an operating facility chasing its first commercial revenues. To reach this point, the parent has poured in more than five thousand crore rupees, and the next phase, where revenue arrives from Q3 FY27 and break-even hinges on how fast the plant fills up, is where an ambition of this size either proves out or strains.

Here is what the ₹5,200 crore commitment actually tells you about Exide’s strategic direction, what the commissioning of Phase I means in practical terms, and the specific variables that will decide whether this concentrated bet was correctly sized.

Exide closes ₹100 crore rights issue in EESL as cumulative bet crosses ₹5,200 crore

The mechanics of the latest transaction are straightforward. Exide subscribed to a fresh rights issue of equity in EESL, its wholly owned cell manufacturing arm, on a cash consideration basis at arm’s length. No ownership percentage changed; Exide already held 100% of the subsidiary and still does.

Here is what the tranche involved:

• 2,85,71,428 equity shares allotted
• Face value of ₹10 per share, issued at a premium of ₹25 per share
• Total raised: ₹99.99 crore
• Allotment completed on 29 September 2026

This tranche did not arrive in isolation. In January 2026, Exide’s board approved up to ₹1,400 crore in additional infusions to keep the project moving, and management has executed that approval across multiple tranches through the year. Yesterday’s rights issue is simply the latest instalment in a steady, deliberate drip of capital.

Add it all up and the number lands with real weight.

₹5,202.23 crore invested in EESL as of 29 September 2026

That figure only becomes fully legible against the parent’s own scale. Standalone Exide Industries reported revenue of roughly ₹17,269 crore in FY26. So the cumulative commitment to EESL now equals close to 30% of the parent’s annual turnover, all directed into a subsidiary whose net worth stood at ₹3,991.06 crore as of 31 March 2026 and which has yet to generate meaningful revenue.

For anyone tracking Exide’s balance sheet and capital allocation, the message is unambiguous. This is not a paper reorganisation or an accounting entry. It is a genuine cash commitment at commercial terms, and both the size of the total and the pace at which it has grown deserve scrutiny.

Phase I of Exide’s 6 GWh Bengaluru gigafactory enters commercial operations

The capital has been buying something concrete, and six days before the latest tranche, that something switched on.

EESL commissioned Phase I of its lithium-ion cell manufacturing facility on 23 September 2026 at the Hi-Tech Defense and Aerospace Park in Devanahalli, Bengaluru. Phase I carries a 6 GWh design capacity built on two chemistries, a configuration that hedges the plant against shifts in demand across different end-markets.

The commercial sequencing follows demand readiness. Initial revenue will come from LFP cells serving three-wheelers, telecom, and battery energy storage systems (BESS), stationary units that store power for later use. NMC cells for two-wheelers follow once that line ramps.

Global BESS demand is one of the key demand drivers underpinning the LFP line at Devanahalli, with grid-scale stationary storage contracts offering longer-term, higher-volume offtake compared to the more cyclical two-wheeler segment.

A few facts anchor the facility:

• Total design capacity of 12 GWh across two phases, with Phase II timing dependent on demand signals
• Phase I capital expenditure estimated at approximately ₹6,000 crore through FY28
• Cell manufacturing technology underpinned by a technical collaboration with SVOLT

The six-day gap between commissioning the plant and injecting fresh capital was not coincidental. Exide is funding the ramp-up phase, the stretch that converts a commissioned facility into a revenue-generating one.

That distinction matters for how you read the risk. Until last week, EESL carried construction risk, the danger that a plant might not get built on time or on budget. Now it carries utilisation and commercial risk, the danger that a built plant does not fill fast enough. The nature of the bet has changed, and the next twelve months are where execution pressure is highest.

Where Exide sits in India’s domestic battery manufacturing race

To judge whether the capital intensity makes strategic sense, it helps to see the map Exide is operating on, and that map is defined by a striking gap between ambition and delivery.

India’s Advanced Chemistry Cell Production Linked Incentive scheme (PLI-ACC), launched in October 2021 with an outlay of ₹18,100 crore, targets 50 GWh of domestic battery cell capacity. Beneficiaries must reach 60% domestic value addition within five years. The policy architecture is generous. The delivery has not matched it.

India’s EV battery demand is projected to reach roughly 200 GWh by 2032, a trajectory that gives context to why domestic supply was estimated near 2 GWh at the end of 2025 while demand already approached 17 GWh.

• Target capacity: 50 GWh
• Allocated to beneficiaries: 40 GWh
• Actually commissioned: 1.4 GWh as of October 2025, primarily by Ola Cell Technologies
• Incentives disbursed to any beneficiary: ₹0 as of September 2026

That is the context that gives Exide’s commissioning its real weight. Only 1.4 GWh of the 50 GWh targeted has physically come online, roughly 2.8% of the goal. In a sector where allocation has consistently outrun delivery, an operating gigafactory is a genuine outlier, not a routine headline.

Exide’s approach also carries a higher cost per unit of capacity than its peers, and the reason matters.

Peer per-GWh figures above are drawn from PLI-ACC analysis and have not been independently confirmed. Read carefully, though, Exide’s higher cost reflects its fully integrated cell manufacturing rather than inefficiency. That integration is what qualifies a producer for PLI benefits tied to domestic value addition, so the premium is closer to a deliberate strategic choice than a red flag.

The field is crowded. More than 10 companies, including Tata Agratas, Amara Raja, and Mahindra, are collectively targeting over 100 GWh of additional capacity. For an investor, the read is this: capital intensity is the price of early-mover positioning in a supply-constrained market where domestic capacity of roughly 2 GWh at the end of 2025 sat far below estimated demand near 17 GWh. Whether that price proves a liability or an advantage depends entirely on what happens next.

What the numbers say about risk, break-even, and what has to go right

The forward picture is best read straight from EESL’s own accounts, and they tell an honest ramp-up story.

Turnover rose, yet the loss widened. That combination is exactly what large-scale manufacturing investments produce in their most financially uncomfortable phase, where depreciation and interest on heavy capital expenditure overwhelm still-nascent revenue. Analysts, including commentary carried by The Hindu Business Line, characterise these losses as ramp-up-phase typical rather than a sign of strategic failure.

Break-even is not close. Analyst commentary places it at late FY27 or early FY28, contingent on utilisation climbing above 40-50% of Phase I capacity. The key mitigant against underutilisation is Exide’s existing order book, with customer onboarding across auto and non-auto segments already underway, which separates EESL from purely speculative greenfield projects lacking committed offtake.

Three structural risks could extend the loss phase well beyond current expectations:

• PLI-ACC disbursement delays. Not a single rupee has been disbursed to any beneficiary as of September 2026, and the investment economics assume those incentives eventually arrive.
• A higher cost base. Exide’s ~₹500 crore per GWh sits above peers, raising the break-even utilisation threshold and leaving it more exposed if cell pricing comes under pressure.
• Chemistry or technology shifts. A move away from NMC or LFP, or the arrival of viable solid-state cells, could reduce the value of installed capacity. The dual-chemistry design mitigates this risk but does not remove it.

Solid-state battery commercialisation is the technology shift most likely to affect the residual value of installed LFP and NMC capacity, though the manufacturing hurdles involved mean that the timeline for viable mass-market solid-state cells remains contested among analysts.

For investors in Exide Industries, the calculation is a balance. Near-term earnings dilution weighs against the long-dated optionality of owning one of India’s only operational domestic cell manufacturers. Which way it tips depends heavily on PLI disbursement timing and the utilisation trajectory through FY27. Exide also holds a separate 1.5 GWh assembly capacity via its Nexcharge joint venture, distinct from the EESL cell operation.

Past performance does not guarantee future results. Financial projections are subject to market conditions and various risk factors, and forward-looking break-even estimates are speculative and subject to change based on market developments and company performance.

Five thousand crore in, the real work starts now

The ₹5,202.23 crore total reads best not as a destination but as the price of admission. The two events of the past week, the fresh capital injection and the Phase I commissioning, mark a single shift in the nature of the bet. The money confirms Exide’s commitment is active and ongoing; the plant switching on moves the risk from construction to execution and commercial delivery.

This article is for informational purposes only and should not be considered financial advice. Investors should conduct their own research and consult with financial professionals before making investment decisions.

The Q3 FY27 revenue milestone and the FY27-to-FY28 break-even window are when projections give way to real operating data. That is when the thesis becomes testable rather than theoretical.

Over the next four to six quarters, four variables will tell you far more than any single capital announcement:

• Utilisation rates at the Bengaluru plant, the single biggest driver of the path to break-even
• PLI-ACC disbursement announcements from the government, the missing piece in the investment economics
• Order book conversion into actual booked revenue across auto and non-auto customers
• Any Phase II capacity commitment from Exide’s board, which would signal management confidence in sustained demand

For anyone tracking India’s EV supply chain, EESL’s ramp-up is now a live test case for whether domestic cell manufacturing at scale is viable under current policy and market conditions. The commission-and-fund sequence is not a conclusion. It is the inflection point where the real work begins.

For readers tracking whether India’s policy framework is structurally suited to close the delivery gap, our full explainer on domestic cell manufacturing coordination examines how government and industry alignment shapes the gap between announced capacity and actual commissioned output globally.